



MOBILisE

ERA CHAIR



Deliverable D36 (D7.2)

Dissemination Plan



The project MOBILisE received funding from the European Union's Horizon 2020 research and innovation programme under Grant Agreement no. 951723.

Project acronym	MOBILISE
Project name	Molecular Bioengineering in health ERA chair
Call	H2020-WIDESPREAD-2018-2020-6
Grant Agreement ID	951723
Project Duration	1 st January 2021 – 30 th June 2026 (66 months)
Coordinator	Cristina Martins INEB – Instituto Nacional de Engenharia Biomédica
Number of Deliverable	D36 (D7.2)
Title of Deliverable	Dissemination Plan
Related WP	WP7 – Communication, dissemination and exploitation
Author(s)	Mariana Bexiga, Cristina Barrias
Contact e-mail(s)	mariana.bexiga@i3s.up.pt ; cbarrias@ineb.up.pt
Dissemination level	Public
Due date	31 st December 2021
Date of Submission	15 th March 2022
Version	1.0

Document History

Version	Date	Status
0.1	20220107	First draft by Mariana Bexiga
0.2	20220120	Second draft after revision by Cristina Barrias
0.3	20220214	Third draft after revision by Helena Azevedo
1.0	20220302	Final version after revision and approval by the Management Committee

Index

Index	2
List of Abbreviations	3
Executive Summary	4
1. Introduction	5
2. Target Stakeholders	5
3. MOBILISE Dissemination Plan.....	6
4. Open Access	10
5. Acknowledgment of EC funding	10

List of Abbreviations

EC	European Commission
ERA-CH	ERA Chair holder
ESB	European Society for Biomaterials
ESGCT	European Society for Gene and Cell Therapy
OA	Open Access
TBA	To be announced
TERMIS	Tissue Engineering and Regenerative Medicine International Society

Executive Summary

MOBILISE aims to recruit an outstanding researcher (ERA Chair holder) to establish a research group and develop a new research line in the field of Molecular Bioengineering at INEB/i3S. Dissemination of the project results and its achievements is, therefore, paramount for the success of MOBILISE. The Dissemination Plan of MOBILISE will raise awareness of the project outputs to all relevant stakeholder groups and is tailored to the needs of each particular audience. It identifies the stakeholders of MOBILISE, including their perceived relevance of MOBILISE, and it defines the type and timing of the dissemination activities for each specific stakeholder group. Furthermore, some external events where MOBILISE could disseminate its outcomes are listed. Finally, the approach of the project towards Open Access is presented.

1. Introduction

A key objective of research supported by public funding is to exploit and achieve maximum impact of the arising research results, which goes beyond the mere production and dissemination of new scientific knowledge. An integrated plan will be deployed to ensure production of high-quality innovative research results, coherent and timely dissemination of the results, as well as focussed and market-oriented valorisation of relevant project outcomes.

MOBILiSE adheres to the principles of innovative research for a cost-effective, competitive and innovative healthcare system by developing solutions for improved healthcare based on molecular bioengineering. Innovation will be pursued by cross-discipline interactions within the INEB/i3S Research Programmes and also by cross-sector collaborations (with clinicians and with industrial partners). MOBILiSE expects to demonstrate the benefits of deep and early engagement of clinicians who will be involved in the co-design of novel emerging technologies.

The Dissemination Plan of MOBILiSE will raise awareness of the project outputs to all relevant stakeholder groups. To maximise the impact of the obtained results, MOBILiSE will foster close links with research groups working in similar sectors, future end-users and key opinion leaders, ensuring that its outcomes are uptaken by the academic, industrial and healthcare communities. To ensure all new knowledge is integrated and contributes towards the increase of the innovation capacity at INEB/i3S and the University of Porto ecosystem, at regional, national and European levels, MOBILiSE will: (i) disseminate its results and its good practices regarding capacity building activities to projects in similar subjects; and (ii) ensure the dissemination and incorporation of new knowledge within INEB/i3S, fostering cross-border innovation in Molecular Bioengineering.

All team members of MOBILiSE will actively participate in the dissemination of the project results in order to maximise the impact of the project. This will be done in a coordinated manner and according to the planned strategy defined in *D7.4 Stakeholder Engagement Plan*. All dissemination activities will follow the visual guidelines defined in *D7.1 Communication Toolkit*.

2. Target Stakeholders

The project will establish and foster contacts with several MOBILiSE stakeholders at early stages to ensure their inputs are adopted in the design process and achieve more relevant and successful outputs. The stakeholders of MOBILiSE are identified on Table 1 along with the project impact relevant to them. The Dissemination plan will ensure that the right target groups among stakeholders will receive the adequate information and will contribute to the project with specific feedback. This list is further refined in *D7.4 Stakeholder Engagement Plan*, which also includes the strategies and actions to engage them.

Table 1. Target stakeholders of MOBILisE and impact of the project

Sector	Stakeholder	Impact of the Project relevant to stakeholder
Academic	Students, Faculty staff, Course leaders	Increase the number of PhD students and future scientists with specific training in Molecular Bioengineering, impacting in areas of Healthcare applications.
Research and Development	Scientists, Research Institutes and R&D companies	Advanced knowledge in new molecularly designed biomaterials, new methodologies, improved technologies and processes that can be adapted and taken up by the Research and Development institutions in this sector. Networking activities.
Research and Development	Other projects, initiatives, networks	Shared knowledge, training and increased international networking
Healthcare sector	Physicians, patients, patient associations	Improved therapies and clinical decision-making. Improved management of disease and quality of life for patients. Improved literacy of patients in new technological advances in precision medicine.
Policy Makers	Local, national and European Regulatory bodies. Science and Technology Managers.	New knowledge, diagnostic and therapeutic tools and therapies that will improve medical care, reducing the impact on society associated to cancer, infection, neurodegenerative diseases, and tissue repair/regeneration.
Public Authorities	Hospitals, primary care medical centres, health managers.	Improved therapies and clinical decision-making. Improved literacy of health sector workers in new technological advances in medicine.
Market	Pharma, diagnostic, Medical device companies	New markets. New therapies.

3. MOBILisE Dissemination Plan

The dissemination strategy during and beyond the project was designed to ensure transparent information access, while respecting all confidentiality and Intellectual Property Rights issues. The summary of the dissemination plan and expected main outputs of the new research group as stated on the GA is shown on Table 2. A calendar of external events in which the researchers of MOBILisE can participate is detailed on Table 3. This working document will be used to implement project dissemination and will be updated for strategy planning in months 36 and 60 of the project.

Table 2. MOBILISE Dissemination Plan

Type of Dissemination	Target Audience	Where (examples)	Target outcome
Manuscripts in peer-reviewed scientific journals	Scientific, Academic and Medical Community	Journal of Controlled Release, Biomaterials, Advanced Healthcare Materials, Nanomedicine, Nature Communications, Advanced Drug Delivery, etc.	4 papers/year
White paper	Scientific/Medical community, Companies, Regulators, Policy Makers, Funding agencies	Websites of the European Commission and MOBILISE.	1 at the end of the project
Presentations at international conferences	Scientific community	Controlled Release Society, European Society for Gene and Cell Therapy (ESGCT), European Society for Biomaterials (ESB), BioNanoMed, Tissue Engineering and Regenerative Medicine International Society (TERMIS).	30 conferences (12 oral and 18 poster presentations) by the end of the project
Presentations at international conferences	Medical Community	European Society for Medical Oncology, European Congress of Clinical Microbiology and Infectious Diseases, European Society of Radiology, Orthopaedic Research Society.	6 conferences (all oral communications)
Molecular Bioengineering seminars	Scientific and Academic communities	INEB/i3S	4 seminars/year (2 by ERA Chair team and 2 by invited speakers)
International Symposium on Molecular Bioengineering	Scientific, Academic and Medical Community	INEB/i3S	1 event/year (from year 2 onwards)
MOBILISE Conference	General public, Scientific/Academic leaders in the field, Industrial developers, Clinicians, other relevant stakeholders	INEB/i3S	1 event at the end of the project

Graduate theses	Academic/Scientific community	University of Porto and other Universities associated with the ERA-CH.	Minimum 2 PhD and 12 MSc theses
-----------------	-------------------------------	--	---------------------------------

Table 3. External events: relevant international conferences and dates for 2022-2023

Community	Conference	Next Conference	End call for abstracts
Scientific Community	32 nd Annual meeting of ESB https://www.esbbordeaux2022.org/	04 – 08 Jun 2022 Bordeaux, France	28 Feb 2022
	2022 TERMIS-EU https://eu2022.termis.org/	28 Jun – 01 Jul 2022 Krakow, Poland	15 Feb 2022
	Controlled Release Society 2022 Annual Meeting and Expo https://www.controlledreleasesociety.org/crs-2022-annual-meeting-and-expo	11 – 15 Jul 2022 Montreal, Canada	31 Jan 2022
	ESGCT 29 th Annual Congress https://www.esgctcongress.com/	11 – 14 Oct 2022 Edinburgh, UK	TBA
	2023 TERMIS-EU http://www.termis.org/eu2020	27 – 30 Mar 2023 Manchester, UK	TBA
	ESGCT 30 th Annual Congress	24 – 27 Oct 2023 Brussels, Belgium	TBA
	Medical Community	The 17 th Annual Peptide Therapeutics Symposium https://peptidetherapeutics.org/symposium/	20 – 21 Oct 2022 San Diego, USA

	ARVO 2023, Annual meeting of The Association for Research in Vision and Ophthalmology https://www.arvo.org/annual-meeting/meeting-info/future-annual-meetings/	23 – 27 Apr 2023 New Orleans, USA	TBA
	International Conference on Dentistry, Dental Medicine and Technology https://waset.org/dentistry-dental-medicine-and-technology-conference-in-june-2023-in-barcelona	10 – 11 June 2023 Barcelona, Spain	1 st July 2022
	International Conference on Dentistry, Dental Medicine and Technology https://waset.org/dentistry-dental-medicine-and-technology-conference-in-june-2023-in-barcelona	10 – 11 June 2023 Barcelona, Spain	1 st July 2022

TBA – To be announced

4. Open Access

The H2020 guidelines for Open Access (OA) publishing will be followed and OA costs have been budgeted for. The approach of MOBILISE towards OA and Open Data has been described in D1.7 *Data Management Plan*. Specifically, a combination of Gold and Green OA strategies will be followed to maximise the dissemination of the results to both scientific and non-scientific public, while observing adequate Intellectual Property protection for exploitable results. All publications arising from the MOBILISE project will be published on an OA basis with the senior author deciding whether to follow the Green or the Gold OA route. Nonetheless, all published scientific results will be deposited in the Open Repository of the University of Porto (<https://repositorio-aberto.up.pt/>), which is part RCAAP (<https://www.rcaap.pt/>), a portal which collects, aggregates and indexes OA Scientific contents from Portuguese institutional repositories. An embargo period may apply, after which the full content of the publications shall be made available. The policy applies to articles in scientific journals, books, books of abstracts, conference proceedings, posters, monographs and thesis. Data Management will follow the FAIR (Findable, Accessible, Interoperable, Reusable) principles for scientific data management and stewardship.

5. Acknowledgment of EC funding

Funding from the European Commission (EC) must be clearly acknowledged on every document and presentation produced. This should be accomplished on the title page of the publication or in a separate acknowledgment section and should contain the EC logo and/or an acknowledgment phrase. Visual materials for this purpose have been produced and are present in D7.1 *Communication Toolkit*.

Non-scientific publications (e.g. newsletters, articles on the website), as well as presentations on scientific congresses or meetings, should include the EC logo and the following statement: *"This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 951723"*. Scientific papers should only include the acknowledgment statement.